<SEC-DOCUMENT>0001193125-23-177586.txt : 20230628
<SEC-HEADER>0001193125-23-177586.hdr.sgml : 20230628
<ACCEPTANCE-DATETIME>20230628165543
ACCESSION NUMBER:		0001193125-23-177586
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230628
DATE AS OF CHANGE:		20230628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272659
		FILM NUMBER:		231052939

	BUSINESS ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d518444d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-272659 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g518444g43a99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 19,509,749 Shares of Common Stock Offered by the Selling Stockholders </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading &#147;Selling
Stockholders&#148; in this prospectus, or their assigns (the &#147;Selling Stockholders&#148;), of up to 19,509,749 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, par value $0.01 per share (the &#147;Common Stock&#148;) which
consist of (i)&nbsp;2,916,358 shares of Common Stock, issuable upon conversion of 9,624 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Convertible Preferred Stock, par value $0.01 per share (the &#147;Series <FONT
STYLE="white-space:nowrap">F-2</FONT> Preferred Stock&#148;), (ii)&nbsp;7,746,436 shares of Common Stock issuable upon conversion of 34,860 shares of <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock exercisable pursuant to the preferred
stock tranche A warrants (the &#147;Preferred Tranche A Warrant&#148;) to acquire shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock, par value $0.01 per share (the &#147;Series <FONT STYLE="white-space:nowrap">F-3</FONT>
Preferred Stock&#148;), (iii)&nbsp;4,149,994 shares of Common Stock issuable upon conversion of 24,900&nbsp;shares of <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock exercisable pursuant to the preferred stock tranche B warrants (the
&#147;Preferred Tranche&nbsp;B Warrant,&#148; together with the Preferred Tranche A Warrant, the &#147;Preferred Warrants&#148;) to acquire shares of <FONT STYLE="white-space:nowrap">Series&nbsp;F-4</FONT> Preferred Stock, par value $0.01 per share
(the &#147;Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock&#148; and together with the <FONT STYLE="white-space:nowrap">Series&nbsp;F-3</FONT> Preferred Stock, the &#147;Preferred Warrant Shares&#148;), (iv) 4,649,185 shares of
Common Stock, (v)&nbsp;31,110 shares of Common Stock, issuable upon exercise of the common stock tranche A warrants (&#147;Common Tranche A Warrant&#148;) and (vi) 16,666 shares of Common Stock issuable upon exercise of common stock tranche B
warrants (the&nbsp;&#147;Common Tranche B Warrant&#148;, together with the Common Tranche A Warrant, the &#147;Common Warrants,&#148; and together with the Preferred Warrants, the &#147;Warrants&#148;). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of the Shares held by the Selling Stockholders to satisfy the registration rights they were granted
pursuant to the Preferred Purchase Agreement (as defined below) and the Common Purchase Agreement (as defined below) (together, the &#147;Purchase Agreements&#148;). While we will not receive any proceeds from the sale of the Shares by the Selling
Stockholders, we will receive proceeds from the exercise of any Warrants for cash. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registration of the Shares covered by this
prospectus does not mean that the Selling Stockholders will offer or sell such Shares. The Selling Stockholders may sell the Shares covered by this prospectus in a number of different ways and at varying prices. For additional information on the
possible methods of sale that may be used by the Selling Stockholders, you should refer to the section of this prospectus entitled &#147;Plan of Distribution.&#148; The Selling Stockholders may, individually but not severally, be deemed to be an
&#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), of the Shares that they are offering pursuant to this prospectus. The Selling Stockholders will bear all commissions and
discounts, if any, attributable to their respective sales of the Shares hereunder. We will bear all costs, expenses and fees in connection with the registration of the Shares. We will not be paying any underwriting discounts or commissions in this
offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add, update, or change information contained in this prospectus. You should carefully read this
prospectus, any applicable prospectus supplement, and the information incorporated by reference in this prospectus and any applicable prospectus supplement before you make your investment decision. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on The Nasdaq Capital Market under the symbol &#147;DCTH.&#148; On June&nbsp;27, 2023, the closing price for our
Common Stock, as reported on The Nasdaq Capital Market, was $6.06 per share. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
these securities involves certain risks. See &#147;<A HREF="#tx518444_4">Risk Factors</A>&#148; on page 6 of this prospectus. See also &#147;Risk Factors&#148; in the documents incorporated by reference in this prospectus for a discussion of the
factors you should carefully consider before deciding to purchase these securities. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is June 28, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx518444_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> which we have filed with the
Securities and Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Stockholders may from time to time sell the Shares described in this prospectus in one or
more offerings or otherwise as described under &#147;Plan of Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may be supplemented from time to time by
one or more prospectus supplements. Such prospectus supplements may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus
supplement, you must rely on the information in the prospectus supplement. You should carefully read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#147;Where You Can
Find More Information&#148; before deciding to invest in any Shares being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Stockholders have
authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus or in any applicable prospectus supplement or any applicable free writing prospectus that we have authorized. If anyone provides,
or has provided you, with different or inconsistent information, you should not rely on it. The Shares are not being offered in any jurisdiction where the offer is not permitted. You should not assume that the information contained in or
incorporated by reference in this prospectus is accurate as of any date other than the respective dates of such document. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to, &#147;Delcath,&#148; &#147;the Company,&#148; &#147;we,&#148;
&#147;our,&#148; or &#147;us&#148; mean Delcath Systems, Inc. and its wholly owned subsidiaries. The term &#147;Selling Stockholders&#148; refers, collectively, to the selling stockholders named under the heading &#147;Selling Stockholders&#148; in
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to the Selling Stockholders in this prospectus, we are referring to the persons names as the Selling
Stockholders in this prospectus and, as applicable, any donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling the Shares received after the
date of this prospectus from the Selling Stockholders as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus summary highlights certain information about us and selected information contained elsewhere in or incorporated by reference
into this prospectus. This prospectus summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of the Company, you should read and consider
carefully the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement or amendment, including the factors described under the heading &#147;Risk Factors<I>,</I>&#148; beginning on
page 5 of this prospectus, as well as the information incorporated herein by reference, before making an investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product
candidate, the HEPZATO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> KIT (melphalan hydrochloride for injection/hepatic delivery system) ( &#147;HEPZATO&#148;), is a drug/device combination product designed to administer high-dose
chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride,
and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (&#147;CHEMOSAT&#148;), where it has been used at major medical centers to treat a wide range of cancers of the liver. Approximately consisting primarily of
metastatic ocular melanoma (&#147;mOM&#148;). Approximately 80% of the estimated 800 patients annually with mOM will be eligible for would be candidates of HEPZATO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the United States Food and
Drug Administration (the &#147;FDA&#148;). Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA&#146;s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in
the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular
carcinoma). HEPZATO has not been approved for sale in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical development program for HEPZATO is comprised of the
FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the &#147;Focus Trial&#148;), a global registration clinical trial that is investigating objective response rate in mOM, a type of primary liver cancer. Our most advanced
development program is the treatment of mOM. We are currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of
<FONT STYLE="white-space:nowrap">follow-on</FONT> indications that will maximize the value of the HEPZATO platform. In addition to HEPZATO&#146;s use to treat mOM, we believe that HEPZATO has the potential to treat other liver dominant cancers, such
as Metastatic Colorectal Cancer and Cholangiocarcinoma, and plan to begin the study of HEPZATO to treat such conditions in the near future. We believe that the disease states we are investigating and intend to investigate are unmet medical needs
that represent significant market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2023, we submitted a NDA resubmission to the FDA for the HEPZATO
Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval of the HEPZATO Kit in the treatment of patients with unresectable hepatic-dominant mOM. The resubmission is in response to a September&nbsp;12, 2013 Complete
Response Letter (&#147;CRL&#148;), from the FDA for our NDA in December 2010 seeking approval of its first generation melphalan hydrochloride for injection/hepatic delivery system. The NDA resubmission contains comprehensive data and information on
Generation Two HEPZATO Kit relating to the matters identified in the CRL. On March&nbsp;20, 2023, the FDA determined the resubmission constituted a complete response and set a Prescription Drug User Fee Act target action date of August&nbsp;14,
2023. We continue to have early access </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs in the United States to make HEPZATO available to mOM patients. We are focused on continuing to treat these patients with mOM as regulatory approval is sought in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;28, 2022, CHEMOSAT received Medical Device Regulation certification under the European Medical Devices Regulation
[2017/745/EU], which may be considered by jurisdictions when evaluating reimbursement. As of March&nbsp;1, 2022, we assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2023
we entered into the Preferred Purchase Agreement and the Common Purchase Agreement. None of the securities issued pursuant to the Purchase Agreements were initially registered under the Securities Act or any state securities laws, rather, we offered
the securities in reliance on exemption from the registration requirements of the Securities Act by virtue of Section&nbsp;4(a)(2) thereof and Rule 506 of Regulation D under the Securities Act. The registration statement of which this prospectus is
a part relates to the offer and resale of the Shares issued to, or issuable pursuant to, the Purchase Agreements, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred
Securities Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a securities purchase agreement (the &#147;Preferred Purchase Agreement&#148;)
pursuant to which we sold (i) 24,900 shares of Series <FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock, par value $0.01 per share (the &#147;Series <FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock&#148; and together with the
Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock, the &#147;Preferred Stock&#148;), (ii) the
Preferred Tranche A Warrants and (iii)&nbsp;the Preferred Tranche B Warrants for an aggregate offering price of $24.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series F Convertible Voting Preferred Stock (the
&#147;Certificate of Designation&#148;), upon receipt of approval from our stockholders to approve the issuance of (i)&nbsp;all Common Stock issuable upon conversion of the Preferred Stock, each share of Series
<FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock automatically converted into shares of Common Stock and/or, at the election of the holder thereof, shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, in lieu of
Common Stock. On June&nbsp;12, 2023, we received such approval from our stockholders and as a result the 24,900 shares of Series <FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock were subsequently converted into an aggregate of 4,649,185
shares of Common Stock at a conversion price of $3.30 per share and 9,624 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, which are convertible into shares of Common Stock at a conversion price of $3.30 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate exercise price of the Preferred Tranche A Warrants is approximately $34.8&nbsp;million, exercisable for an aggregate of up to
34,860 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock until the earlier of 21 days following the Company&#146;s announcement of receipt of approval from the FDA for HEPZATO and March&nbsp;31, 2026 (such approval, the
&#147;FDA Approval&#148;). The 34,860 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock are convertible into an aggregate of 7,746,436 shares of Common Stock at a conversion price of $4.50 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate exercise price of the Preferred Tranche B Warrants is approximately $24.9&nbsp;million, exercisable for an aggregate of up to
24,900 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock until the earlier of 21 days following the Company&#146;s announcement of receipt of recording at least $10&nbsp;million in quarterly U.S. revenue from the
commercialization of HEPZATO and March&nbsp;31, 2026; provided, however, that if the FDA Approval occurs on or before February&nbsp;15, 2024 and the holder of the Preferred Tranche B Warrant has not exercised its Preferred Tranche A Warrant by or
before March&nbsp;7, 2024, then any Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock not yet exercised pursuant to the Preferred Tranche B Warrant at such time shall expire. The 24,900 shares of Series <FONT
STYLE="white-space:nowrap">F-4</FONT> Preferred Stock are convertible into an aggregate of 4,150,000 shares of Common Stock at a conversion price of $6.00 per share. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Securities Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a securities purchase agreement (the &#147;Common Purchase Agreement&#148;) pursuant to which we sold (i) 19,646 shares of
Common Stock, (ii)&nbsp;the Common Tranche A Warrants and (iii)&nbsp;the Common Tranche B Warrants for an approximate aggregate offering price of $100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate exercise price of the Common Tranche A Warrants is approximately $139,997, exercisable for an aggregate of 31,110 shares of
Common Stock until the earlier of 21 days following the Company&#146;s announcement of receipt of FDA Approval and March&nbsp;31, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate exercise price of the Common Tranche B Warrants is approximately $99,998, exercisable for an aggregate of 16,666 shares of
Common Stock until the earlier of 21 days following the Company&#146;s announcement of receipt of recording at least $10&nbsp;million in quarterly U.S. revenue from the commercialization of HEPZATO and March&nbsp;31, 2026; provided, however, that if
the FDA Approval occurs on or before February&nbsp;15, 2024 and the holder of the Common Tranche B Warrant has not exercised its Common Tranche A Warrant by or before March&nbsp;7, 2024, then any Common Stock not yet exercised pursuant to the Common
Tranche B Warrant at such time shall expire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware in August 1988. Our principal executive offices are located at 1633 Broadway, Suite 22C, New
York, New York 10019. Our telephone number is (212) <FONT STYLE="white-space:nowrap">489-2100.</FONT> Our website address is http://www.delcath.com. Information contained in, or accessible through, our website does not constitute any part of, and is
not incorporated into, this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock offered by the Selling Stockholders </I></B></P></TD>
<TD>(i) 2,916,358 shares of Common Stock, issuable upon conversion of 9,624 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, (ii) 7,746,436 shares of Common Stock issuable upon conversion of 34,860 shares of <FONT
STYLE="white-space:nowrap">F-3</FONT> Preferred Stock exercisable pursuant to the Preferred Tranche A Warrant, (iii) 4,149,994 shares of Common Stock issuable upon conversion of 24,900 shares of <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred
Stock exercisable pursuant to the Preferred Tranche B Warrant, (iv) 4,649,185 shares of Common Stock, (v) 31,110 shares of Common Stock, issuable upon exercise of Common Tranche A Warrant, and (vi) 16,666 shares of Common Stock, issuable upon
exercise of the Common Tranche B Warrant. See &#147;Selling Stockholders.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds </I></B></P></TD>
<TD>We will not receive any of the proceeds from the sale of the Shares covered by this prospectus, except with respect to amounts received by us due to the exercise of any Warrants for cash. We intend to use the proceeds from the exercise of any
Warrants for cash for working capital and general corporate purposes. See the section of this prospectus titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Risk Factors </I></B></P></TD>
<TD>Investing in our Common Stock involves a high degree of risk. For a discussion of factors to consider before deciding to invest in our Common Stock, you should carefully review and consider the &#147;Risk Factors&#148; section of this
prospectus, as well as the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement or amendment. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq Capital Market Symbol </I></B></P></TD>
<TD>DCTH </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our Common Stock involves a high degree of risk. Before deciding whether to invest in our Common Stock, you should consider
carefully the risks and uncertainties discussed in this section and under the sections titled Risk Factors contained in our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> in our subsequent Quarterly
Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,&nbsp;as</FONT> well as any amendments or updates to our
risk factors reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus, together with other information in this prospectus, the documents incorporated by reference, any prospectus supplement and any free
writing prospectus that we may authorize. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our
business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected.
In that case, the trading price of our Common Stock could decline and you might lose all or part of your investment. Please also read carefully the section titled &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, and the documents incorporated by reference herein, contain, or will contain, &#147;forward-looking statements&#148; within
the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act&nbsp;of 1934, as amended (the &#147;Exchange Act&#148;). Forward-looking statements can be identified by words such as &#147;intends,&#148;
&#147;believes,&#148; &#147;anticipates,&#148; &#147;indicates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;suggests,&#148; &#147;may,&#148; &#147;would,&#148; &#147;should,&#148; &#147;potential,&#148; &#147;designed to,&#148;
&#147;will,&#148; &#147;ongoing,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;predict,&#148; &#147;could,&#148; and similar references, although not all forward-looking statements contain these words. Forward-looking statements are
neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events
and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside
of our control. Risks that could cause actual results to vary from expected results expressed in our forward-looking statements include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions by the FDA relating to our New Drug Application resubmission; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the Company to respond to FDA queries related to our scheduled Prescription Drug User Fee Act
target action dated of August&nbsp;14, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our successful inspections by the FDA or foreign regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement of future clinical trials and the results and timing of those clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain
reimbursement for the procedure and system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and results of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval and approval thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully source certain components of CHEMOSAT and HEPZATO and enter into supplier contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture CHEMOSAT and HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate
partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of potential market opportunities and our ability to successfully realize these opportunities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other factors discussed under the headings &#147;Business,&#148; &#147;Risk Factors&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments or updates to our risk factors reflected in
subsequent filings with the SEC, which are incorporated by reference into this prospectus, together with other information in this prospectus, the documents incorporated by reference, any prospectus supplement and any free writing prospectus that we
may authorize. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date the statements are made. Except as required under
the federal securities laws and rules and regulations of the SEC, we undertake no obligation to update or revise forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking
information. We caution you not to unduly rely on the forward-looking statements when evaluating the information presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of the Shares covered by this prospectus, except with respect to amounts received by us
due to the exercise of any Warrants for cash. We intend to use the proceeds from the exercise of any Warrants for cash for working capital and general corporate purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, including Common Stock issued
upon conversion of the Series <FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock, and the Common Stock issuable to the Selling Stockholders upon exercise, and, if applicable, conversion of the Preferred Warrant Shares. We are registering
the Shares in order to permit the Selling Stockholders to offer the shares for resale from time to time. For additional information regarding the Shares being offered by the Selling Stockholders pursuant to this prospectus, see
&#147;Summary&#151;Private Placement&#148; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the Selling Stockholders and other information regarding the
beneficial ownership of the Common Stock by each of the Selling Stockholders. The second column lists the number of Common Stock beneficially owned by each selling stockholder, based on its beneficial ownership of the Shares, as of June&nbsp;5,
2023, assuming exercise of the Warrants held by the Selling Stockholders on that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fourth column lists the Shares being offered
by this prospectus by the Selling Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Purchase Agreements, as applicable, this prospectus
generally covers the resale of the sum of (i)&nbsp;the aggregate number of Common Stock issued or issuable to the Selling Stockholders as a result of conversion of the Series <FONT STYLE="white-space:nowrap">F-1</FONT> Preferred Stock and/or Series <FONT
STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, (ii)&nbsp;the number of shares of Common Stock issued pursuant to the Common Purchase Agreement and (iii)&nbsp;the number of shares of Common Stock issuable upon exercise of the Warrants (and
conversion, if necessary, of the Preferred Warrant Shares).<B> </B>The fourth column assumes the sale of all of the Shares offered by the Selling Stockholders pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Designation, a Selling Stockholder shall not have the right to convert any portion of the Series F Preferred
Stock and such Series F Preferred Stock shall not be automatically converted, to the extent that after giving effect to such conversion, such Selling Stockholder, together with its affiliates, any other persons acting as a group together, and any
other persons whose beneficial ownership of Common Stock would be aggregated with the Selling Stockholder&#146;s and the other attribution parties for purposes of Section&nbsp;13(d) of the Exchange Act would beneficially own in excess of 9.99% of
the shares of Common Stock outstanding immediately after giving effect to such conversion, excluding for purposes of such determination shares of Common Stock which would be issuable upon exercise of the remaining, unconverted portion of the Series
F Preferred Stock beneficially owned (the &#147;Preferred F Stock Blocker&#148;). Under the terms of the Common Warrants, a Selling Stockholder may not exercise the Warrants to the extent such exercise would cause such selling stockholder, together
with its affiliates and attribution parties, to beneficially own a number of Common Stock which would exceed 9.99% of our then outstanding Common Stock following such exercise, excluding for purposes of such determination Common Stock issuable upon
exercise of the Warrants which have not been exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in the following table has been provided to us by or on behalf of the
Selling Stockholders and the Selling Stockholders may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities. The Selling Stockholders
may sell all, some or none of their Shares in this offering. See &#147;Plan of Distribution.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Prior to<BR>Offering&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Prior to<BR>Offering&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares of<BR>Common<BR>Stock<BR>to be Sold<BR>Pursuant to<BR>the<BR>Prospectus&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After<BR>Offering&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After<BR>Offering*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vivo Opportunity Fund Holdings, L.P. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,880,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Logos Capital (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,880,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with BVF Partners (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,880,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Rosalind Advisors, Inc.&nbsp;(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,678,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,010,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stonepine Capital, LP (7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitchell Robbins (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,178,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">701,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,025,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serrado Opportunity Fund LLC (9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bigger Capital Fund, LP (10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">663,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">District 2 Capital Fund LP (11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ADAR1 Partners, LP (12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Triple Gate Partners, LP (13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerard Michael (14)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">870,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Percentage not listed if less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Beneficial ownership&#148; means that a person, directly or indirectly, has or shares voting or
investment power with respect to a security or has the right to acquire such power within 60 days. The number of shares beneficially owned is determined as of June&nbsp;5, 2023, and the percentage is based upon 10,620,930 shares of our Common Stock
outstanding as of June&nbsp;5, 2023. In computing the number of shares of our Common Stock beneficially owned by a Selling Stockholder and the percentage ownership of such Selling Stockholder, we deemed outstanding shares of Common Stock issuable
upon the exercise (and conversion, if applicable) of the Warrants and Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, held by that Selling Stockholder. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other Selling Stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes sale of all Shares covered by this prospectus and no further acquisitions of shares of Common Stock by
the Selling Stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,178,787 shares of Common Stock. In addition to the foregoing shares of Common Stock, as of
June&nbsp;5, 2023, Vivo Opportunity Fund Holdings, L.P. held (i) 715,454 shares of Common Stock issuable upon conversion of 2,361 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, (ii) 1,944,666 shares of Common Stock
issuable upon conversion of 8,751 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 1,041,833 shares of Common Stock issuable upon conversion of 6,251 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT>
Preferred Stock that are not included in the shares reported under &#147;Total Shares of Common Stock Beneficially Owned Prior to Offering&#148; because they are subject to limitations on exercisability if such exercise would result in Vivo
Opportunity Fund Holdings, L.P. beneficially owning more than 9.99% of our outstanding Common Stock. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. and Gaurav Aggarwal, Kevin Dai, Hongbo Lu, Frank Kung and
Michael Chang are the voting members of Vivo Opportunity, LLC. The Selling Stockholder&#146;s address is c/o Vivo Capital LLC, 192 Lytton Avenue, Palo Alto, CA 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 884,090 shares of Common Stock held by Logos Global Master Fund, LP (&#147;Logos Global&#148;) and
294,697 shares of Common Stock held by Logos Opportunities Fund III, LP (&#147;Logos Opportunities&#148;, and together with Logos Global, the &#147;Logos Entities&#148;). In addition to the foregoing shares of Common Stock, as of June&nbsp;5, 2023,
(i) Logos Global held 536,566 shares of Common Stock issuable upon conversion of 1,771 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, 486,000 shares of Common Stock issuable upon conversion of 2,187
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 260,333 shares of Common Stock issuable upon conversion of 1,562 shares of Series
<FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock and (ii)&nbsp;Logos Opportunities held 178,787 shares of Common Stock issuable upon conversion of 590 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, 1,458,444
shares of Common Stock issuable upon conversion of 6,563 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 781,333 shares of Common Stock issuable upon conversion of 4,688 shares of Series <FONT
STYLE="white-space:nowrap">F-4</FONT> Preferred Stock that are not included in the shares reported under &#147;Total Shares of Common Stock Beneficially Owned Prior to Offering&#148; because they are subject to limitations on exercisability if such
exercise would result in the Logos Entities beneficially owning more than 9.99% of our outstanding Common Stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 630,303 shares of Common Stock held by Biotechnology Value Fund, L.P. (&#147;BVF LP&#148;), 481,515
shares of Common Stock held by Biotechnology Value Fund II, L.P. (&#147;BVF2 LP&#148;), 51,515 shares of Common Stock held by Biotechnology Value Trading Fund OS LP (&#147;BVF OS&#148;) and 15,454 shares of Common Stock held by MSI BVF SPV, LLC
(&#147;MSI BVF&#148;), and together with BVF LP, BVF2 LP and BVF OS, the &#147;BVF Entities&#148;). In addition to the foregoing shares of Common Stock, as of June&nbsp;5, 2023, (i) BVF LP held 381,818 shares of Common Stock issuable upon conversion
of 1,260 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, 1,039,111 shares of Common Stock issuable upon conversion of 4,676 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 556,666 shares
of Common Stock issuable upon conversion of 3,340 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock, (ii)&nbsp;BVF2 LP held 288,181 shares of Common Stock issuable upon conversion of 951 shares of Series <FONT
STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, 790,222 shares of Common Stock issuable upon conversion of 3,556 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 423,333 shares of Common Stock issuable upon
conversion of 2,540 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock, (iii)&nbsp;BVF OS held 36,363 shares of Common Stock issuable upon conversion of 120 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT>
Preferred Stock, 90,222 shares of Common Stock issuable upon conversion of 406 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 48,333 shares of Common Stock issuable upon conversion of 290 shares of Series <FONT
STYLE="white-space:nowrap">F-4</FONT> Preferred Stock and (iv)&nbsp;MSI BVF held 8,787 shares of Common Stock issuable upon conversion of 29 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, 24,888 shares of Common Stock
issuable upon conversion of 112 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and 13,333 shares of Common Stock issuable upon conversion of 80 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred
Stock, certain of which are not included in the shares reported under &#147;Total Shares of Common Stock Beneficially Owned Prior to Offering&#148; because they are subject to limitations on conversion if such conversion would result in the BVF
Entities beneficially owning more than 9.99% of our outstanding Common Stock. BVF I GP LLC is the general partner of BVF LP. BVF II GP LLC is the general partner of BVF2 LP. BVF Partners OS Ltd. is the general partner of BVF OS. BVF GP Holdings is
the sole member of BVF I GP LLC and BVF II GP LLC. BVF Partners L.P. is the sole member of BVF Partners OS Ltd. and investment manager of BVF LP, BVF2 LP, BVF OS and MSI BVF. BVF Inc. is the general partner of BVF Partners L.P. Mark N. Lampert is
director and officer of BVF Inc. Each of BVF I GP LLC, BVF II GP LLC, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P. BVF Inc. and Mr.&nbsp;Lampert disclaims beneficial ownership of securities beneficially owned by the Selling
Stockholders. The Selling Stockholder&#146;s address is c/o BVF Partners L.P., 44 Montgomery St, 40<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, San Francisco, CA 94104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 938,828 shares of Common Stock and 239,959 shares of Common Stock held by entities affiliated with
Rosalind Advisors, Inc. which includes Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P. (&#147;Rosalind&#148;) issuable upon exercise of 239,959 warrants (the &#147;Rosalind Warrants&#148;). In addition to the foregoing shares of
Common Stock, as of June&nbsp;5, 2023, Rosalind held (i) an aggregate of 219,180 shares of Common Stock issuable upon the conversion of an aggregate 2,192 shares of Series E Preferred Stock, at a conversion rate of $1,198 per share, following an
election by Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P. to convert an aggregate $2 million principal amount of 8% senior secured promissory notes issued by the Company to such Selling Stockholders, together and with all accrued
interest thereon into shares of Series E Preferred Stock (ii) 914,865 shares of Common Stock issuable upon conversion of 9,148 shares of Series E Preferred Stock, (iii)&nbsp;an aggregate of 175,256 shares of Common Stock issuable upon the conversion
of an aggregate 1,752 shares of Series <FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock, (iv) 480,006 shares of Common Stock issuable upon exercise of the Rosalind Warrants, (v) 651,515 shares of Common Stock issuable upon conversion of
2,150 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, (vi) 668,888 shares of Common Stock issuable upon conversion of 3,010 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (vii) 358,333
shares of Common Stock issuable upon conversion 2,150 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
foregoing clauses (i)&nbsp;through (vii) reflect securities convertible into shares of Common Stock, all of which are subject to a beneficial ownership blocker that otherwise limits their ability
to exercise or convert such security if such exercise would result in beneficially owning more than 9.99% of our outstanding Common Stock and therefore such securities are not included in the shares reported under &#147;Total Shares of Common Stock
Beneficially Owned Prior to Offering.&#148; Mr.&nbsp;Salamon and Dr.&nbsp;Aharon are members of the Board of Directors of the Company pursuant to a Board Appointment Agreement. Mr.&nbsp;Salamon and Dr.&nbsp;Aharon disclaim beneficial ownership with
respect to these securities. The Selling Stockholder&#146;s address is c/o Rosalind Advisors, Inc., 15 Wellesley Street West, Suite 326, Toronto, ON M4Y OG7. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 378,787 shares of Common Stock, (ii) 388,888 shares of Common Stock issuable upon conversion of
1,750 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 208,333 shares of Common Stock issuable upon conversion of 1,250 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. The Selling
Stockholder&#146;s address is Stonepine Capital Management, Attn: Jeff Nunnenkamp, 919 NW Bond Street, Suite 204, Bend, OR 97703. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,178,787 shares of Common Stock. In addition to the foregoing shares of Common Stock, as of
June&nbsp;5, 2023, Mitchell Robbins held (i) 118,787 shares of Common Stock issuable upon conversion of 392 shares of Series <FONT STYLE="white-space:nowrap">F-2</FONT> Preferred Stock, (ii) 279,555 shares of Common Stock issuable upon conversion of
1,258 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 149,833 shares of Common Stock issuable upon conversion of 899 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock that are not
included in the shares reported under &#147;Total Shares of Common Stock Beneficially Owned Prior to Offering&#148; because they are subject to limitations on exercisability if such exercise would result in Mitchell Robbins beneficially owning more
than 9.99% of our outstanding Common Stock. The Selling Stockholder&#146;s address is 461 South Maya Palm Drive, Boca Raton, FL 33432. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 181,818 shares of Common Stock, (ii) 186,666 shares of Common Stock issuable upon conversion of
840 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 100,000 shares of Common Stock issuable upon conversion of 600 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. The Selling
Stockholder&#146;s address is Serrado Capital LLC (c/o Stewart Hen), 40 Worth Street, Suite 702, New York, NY 10013. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 386,712 shares of Common Stock, (ii) 77,777 shares of Common Stock issuable upon conversion of
350 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock, (iii) 41,666 shares of Common Stock issuable upon conversion of 250 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock and (iv) 157,554
shares of Common Stock which may be acquired upon exercise of certain common stock warrants. Michael Bigger has the power to vote or dispose of the shares owned by Bigger Capital Fund, LP, Matthias Bigger&#151;UTMA and the Andreas Bigger Irrevocable
Trust Agreement. The Selling Stockholder&#146;s address is 11700 W Charleston <FONT STYLE="white-space:nowrap">Blvd&nbsp;170-659,&nbsp;Las</FONT> Vegas, NV 89135. Michael Bigger disclaims beneficial ownership over these securities.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 236,385 shares of Common Stock, (ii) 34,722 shares of Common Stock which may be acquired upon
exercise of certain common stock warrants, (iii) 77,777 shares of Common Stock issuable upon conversion of 350 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iv) 41,666 shares of Common Stock issuable upon
conversion of 250 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. Michael Bigger has the power to vote or dispose of the shares owned by District 2 Capital Fund LP. The Selling Stockholder&#146;s address is 14 Wall
Street, 2nd&nbsp;Floor, Huntington, New York 11743. Michael Bigger disclaims beneficial ownership over these securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 161,608 shares of Common Stock, (ii) 155,555 shares of Common Stock issuable upon conversion of
700 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 83,333 shares of Common Stock issuable upon conversion of 500 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. The Selling
Stockholder&#146;s address is 3503 Wild Cherry Drive, Building 9, Austin, TX 78738. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 392,935 shares of Common Stock,(ii) 77,777 shares of Common Stock issuable upon conversion of
350 shares of Series <FONT STYLE="white-space:nowrap">F-3</FONT> Preferred Stock and (iii) 41,667 shares of Common Stock issuable upon conversion of 250 shares of Series <FONT STYLE="white-space:nowrap">F-4</FONT> Preferred Stock. The Selling
Stockholder&#146;s address is 445 Central Ave, Suite 317, Cedarhurst, NY 11516. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 177,589 shares of Common Stock, (ii) 645,502 shares of Common Stock that may be acquired
through the exercise of options, (iii) 47,776 shares of Common Stock, issuable upon exercise of the Common Warrants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2020, we entered into a Board Appointment Agreement, dated as of April&nbsp;8, 2020, with Rosalind, pursuant to which Steven
Salamon and Gil Aharon, who are principals of Rosalind, have been appointed as directors of the Company&#146;s board of Directors. Certain shares of Common Stock registered for resale hereunder are also held by Gerard Michel, who is the Chief
Executive Officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than this relationship with Rosalind and Gerard Michel, none of the Selling Stockholders has had
a material relationship with us or any of our predecessors or affiliates within the past three years, other than as a result of the ownership of our shares of Common Stock or other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders, which includes any of their pledgees, assignees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their Shares covered hereby on the principal trading market or any other stock exchange, market or
trading facility on which the Common Stock are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling the Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker dealer as principal and resale by the broker dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker dealers that agree with the Selling Stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set
forth in a supplements to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to
close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions
or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell
pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealers or
agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or
understanding, directly or indirectly, with any person to distribute the securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay certain fees and expenses that we incur incident to the registration
of the Shares covered by this prospectus. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective continuously effective under the Securities Act until the date that all the Shares being offered
by the Selling Stockholders (i)&nbsp;have been sold pursuant to this registration statement or pursuant to Rule 144, or (ii)&nbsp;may be sold without volume or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 and without the requirement for us to be in compliance with the current public information requirement under Rule 144.
The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been
registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies
of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of Common Stock to be offered for resale by the Selling Stockholders under this prospectus will be passed upon for
us by Cooley LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2022 and 2021 and for each of the two years in the period ended
December&nbsp;31, 2022 incorporated by reference in this prospectus have been so incorporated in reliance on the report of Marcum, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of
said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should
refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to
the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s
website at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access our SEC filings at our website www.delcath.com. Our website and the information
contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on our website or any such information in making your decision
whether to purchase our securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx518444_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus the information contained in other documents we file with the SEC, which
means that we can disclose important information to you by referring you to those documents. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded, for
purposes of this prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We incorporate by reference the documents listed below which have been filed by us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312523079836/d449666d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;27, 2023, including those portions of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> incorporated by reference from
our <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312523128784/d492745ddef14a.htm">definitive proxy statement</A> filed with the SEC on May&nbsp;1, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312523150523/d438134d10q.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the period ended March&nbsp;31, 2023, filed with the SEC on May&nbsp;22, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312523080977/d422467d8k.htm">March
<U></U>&nbsp;28, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312523084121/d377148d8k.htm">March<U></U>&nbsp;
30, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000872912/000119312523162595/d465683d8k.htm">June<U></U>&nbsp;
7, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000872912/000119312523166068/d509714d8k.htm">June<U></U>&nbsp;
13, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312523172534/d655594d8k.htm">June 22, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Common Stock contained in our registration on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520128421/d915262d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-Al2B</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-16133)</FONT> filed with the SEC on April&nbsp;30, 2020, including any amendment or report filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any
portion of any report or documents that is not deemed filed under such provisions, (1)&nbsp;on or after the date of filing of the registration statement containing this prospectus and prior to the effectiveness of the registration statement and
(2)&nbsp;on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed
incorporated by reference in this prospectus and to be a part of this prospectus from the date of filing of those documents and will be automatically updated and, to the extent described above, supersede information contained or incorporated by
reference in this prospectus and previously filed documents that are incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this
prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Upon written or oral request, we will provide without charge to each
person, including any beneficial owner, to whom a copy of the prospectus is delivered a copy of any or all of the reports or documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically
incorporated by reference herein). You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g518444g43a99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 19,509,749 Shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock Offered by the Selling Stockholders </B></P> <P STYLE="font-size:210pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:190pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June 28, 2023 </B></P> <P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g518444g43a99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g518444g43a99.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1B,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &'"^8E8X0DE-! 0      !T< 5H  QLE1QP"   "   < E  "5)A:B!4
M:6QA:P X0DE-!"4      !#UJ-8#(@58B[W)TG-MFSS(.$))300Z      #O
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B
M;V]L      MP<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))30/R       *  #_______\  #A"24T$#0      !
M %HX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$1       $     (
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M            /P   ,@    & &0 <P!P #  ,  S     0
M           !              #(    /P                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    /P    !29VAT;&]N9P   ,@    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   #\     4F=H=&QO;F<   #(     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    #.$))300,      WJ     0
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MLO(OJ%5]GION>]FI#6?H['NK]OJ?HUH?5?ZN70
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M  (1 0,1 ?_$ !X   $$ @,!              <&" D*  4! @,$_\0 2!
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M/%-X"G^'4(?V6%N%;E+R6=E?PV>"FRU5ZC?OO)+&K7KO8#'K>N_4.VO3J/\
M]0>ZV=OVD?C6E;7#LT8XN-H[[*<4^:>@_08NJRDY6G;?^*<Q\F,<?:OMU-K]
MHGI16OY9.2Z\AI6RK^WR%C5<1%ULI^*1,Z 'Y=OAXOI! /KKL2-\M^&8ZNKZ
MA#2TY4NG-JHN(P?\5>;X>;Y.3?Q%I?3[<G6;T\_:>Q?+9[@JL8P9"M;]G*D-
M:*\\I?*KBM<6\78N+N7GJ=791U 1QCJ8]?:1 ._X%E)2 1LZ(^A\=S^,_3]8
M[2$I-C(A01M9ZW;0.)CE1X:CRE/6%Z)KLI2/%-^+J.LL<QQ=;;Y%^$N/S//*
M&\Y_<S_Q6Y3Y1DF/\7RV<>[[FXM[9[D:L,X=2\$^YH7#%=2^JI'AM:U)6LS8
MJ40I1T7U/28=AI1AHQB_3@D=RQ&5 ;Y1E,N4D9L8-[I2(O!)[Z4Y,I+2MH"Y
M4P4#M.!<F+,5O^>\8\NR*NV,K[R^\LY2GS1<M;Q8Y/:<BM+W8.+'?,2F(1Y[
M9WQ<9B*A5E=,O8J!)*%*85%)2"4@OTEUF,CNHZ!/?)A]&6M3"YL=T9Q/?;33
M(Q9MO;T^IW@)])DX]V^,(HX_+496>1PAC..ISIQR<GF>?LTLG><DO3C(9:Q3
MF#8=,K=;H)<G]NA6:H&^LZGL=CUJCY5&JA&^I3*HJWU=^4[#0AI^MFV.T=#4
MU$(XE.0PE*-52!&4L7)G;>YZT]379]BVNXD1;<A&5BV.,T6B;0Z%7V7"A0;\
M_<K9I?@FVC."VI-Y=GL.E4R6^5">H_1++L =R!V*=^-+\<3OM>VB.T^M(7[)
MIG%8*7R8Z!_#GN[G4\T1+H$N.K=!X +_ %OXZAMR3/L[^:5SKM45',O4ZSUD
M\PS&S2ZO%2I'(+%GIX4IE9SLKJLC#%H[U+4HA56K44H[4M1)UHZG8_AS2-L6
MH!:_5M^[4=8;^LW1E\*XR]*/?=UJ.Z:RD\II%KNHME$\!R1B'B,2[*6*/LSM
MYBC(.&,P1[EI3>YMB_)&+\@7S5<8?%C''I,&F##(0SM#O3R.:E-"PP:'RE1)
M2%(2" >0]2_%>CZC*471G"-XE*:VUIJI'1A_A"-,E+LCE=N'H.O,)?5+!95$
M?+:5J4U65J)>%ZD)\XGC-P\Y VN"GOFKRMM^-^*\6B=N7PK:/$.;IED=UFU.
M,TPEG5($RFJHQ0,8(3&H;+*J_?-1/53130?&!V6M/<QTX;M25[23[2HL;DU%
M4H0EMW;9>Z(7UK]SH"6N(YLY;D-!:!X:W 2%BN.JC_F"67E 1R!,D6X#.^:Y
MKE.WD2??T_E%P^(QU=QCI!D/M5Y!8XQ(UR,J+&4F'0Y 0  >L@J/H_HW;=QJ
MC/NHZ,=-C'Z<=,U#6C-9B:I]:4$L:VR?UYZY;O6$+CI[[M5=LH,<5M C+ ')
M2&*QU)]]G%A\ES;B3S'^/-U+'%E@61,6QB*(433<%,$GGS+EJ"/DN86=124B
MX8TT*8I]734K1^EU;[:ROQMH0[/N]-C%S*46EC1]#MT+92,R3-EK&[ZV>PT_
MJ1E;54\7^\ET80C>2Z]U4)U7UYJ<?&KBARIS'QX99;=SJRQ3+$1LR>]:$1UV
M>NMD8"::F2BNI36M'9*C374I]6RE:AHGJOP_ZF/8Z<F-;X[J);JO5UI.2+'%
MUAJ3^7XZPO6]%TI(.,J57'TJYX&W+C/^EWCRY_*KCOEHX^SEFJPS*]Y'<LG8
M-0IW:G>#M$9$40P-#Y.E*3[*0U>HI-4)"*GL]J_BZ$)-0>5Z_J)J]YHC%#2U
M].;+=0HPC5$%?,4:+SC(=3VOI[I=K(L%BM5=&^65E.GD,/!5TT40,!Q7*.0<
MRXXQYARY<+/)>0I"VP*)5&QX^&7%#C-T^XRI;[H#I2E[4I1] $J/Z^/79=YI
MQ]/=2<HQA",ISDJ1C&&JJR]I[0%?)5XK/+=H_3[U@6JQ P7>E(^99S?[I;C*
M]20>91Y/V4O+CQ_BW(LRR=%LELV0'Q4(=PQ-#G'#%)*&=3X&M!>JM7X@C=3]
M^'XFJ]%8?**E)!^7QE^@>M=GZA]73=*46%7*4UW6ZZ)]+,;V<3^G(#\M(R)]
M2[-[7;(_>R8XKZ>%DIQ)IC?FK>IX_LL\[EUWA/D[!'1TN+B$0[(\%>8@TW7=
M3$ZS=DD"ILC82= K9631/;U.^^AQ7XTU.TTM>,M.)%<3E_:7. =N1&2*Q@S9
M& MQSUH^B]Q*8Q441S5!*4]T@ _= SC'*Y+8%:O;T:5>K74*%&V/S+*M)  !
M!U_: !KL?KV[<5#3N48PC<EH+6VG[_%]=-+ W]G'/A.HT<I\K)I)Y-<07!#9
M<7/2%VRI%;-1<;YZ'3LEB!(2 G6^M0"O7NG8'CH^W],-F[4J(&Z:H0B&Z\NI
M$H#,I<95..L?6[F1)(A;48T7*5\71;;6##Q6%Z1E5HYS1ZF9"+B9W6MWAM/B
M5ED>M]^DL>AW';>^^CH ]]TL>TDL8_2N.$Q3]HN!\H"F&^>B]VH4Y7GQ]F\6
M^:QF\'1[P/RF5.7&E LE6YC<X.[.RO-*L6U\) 'NCV:5I+)(D[V:22%*2-4U
M=?2GP+J=N1%CYM2E1<[KW6M-['GPB OOM/L1*^WD+&AK$N>;O.U^GC,Z-ZSP
MNEUGA=+JN9]ILD7NSR[6!K'82CD7C%D!_4L\[??3O]6+ZZ]/R.STWX3^A'O6
M6HU#Z<R+[WW,9)Q<OFEQ_H=9/K<5T0/"8?\ \H#\9_F?QZJ@^69YEK_Y:TPR
MK-X_B=ERPX9-CD9C-Y:N<O>(Y[A#(ZJ>2%"I&".DI6ON!W/IH>.]]8],[+OM
M.!]2>GM93&$9*W$@Q6;,;W-X$D%J62Y7LN]U.UDE%)7E\LELBOYJ+M\E7@WG
M/#S..4?F@/\ #($ZQ6W9(4S/5.^@V%,56K[*/?TFICV5-U>.I1DDY>Z:.KV=
MM;II4$%51::8J5:BEV]G^'/2?3-,8Z\M284SG#N(3E;/*&JP$)I^0LYN64CU
M.<^\0C6!HL(F8,EMA:L;W*JYO!U98\D/RGIEQVP;F+(O(MMN(EEKDK#7/'Z8
M9=I%1QQUB][14MUT752:NT220W*K>I=Q\H72HHCT>H*/M/:JH<5Z_P"M0^II
MP[>>_3T-6.H3-K&4XD5A%EI26<)RMRENPMW!H>D>F.E%DE;H 1;&-,_=*IY)
M%IS=KQ[FI.YP/(GET<R[)ISSA:/3-YQ!.573KCK(\:0YXXRK&5I5'PNG\2(J
MTWYAD\=(5!I14IU4]8Z5(6GJ2>YTWT[O]!^EK5'6@D=72^I<+OW1W1V$XHV2
M@D9%2@HQ,V'93[>0RC;%R-4<M5O5'=5C[C)5WU.*]>=+Y5-O&EW,8\IK'CM+
MBK=TSR. 8 :XP'(=]!\3'):LZT2>J(J^@[ GQS/=_APW7J>H.OGA[8T\>S$F
M&J2E6 DA]\VNG'U".G$B:9&O));RCC:@>[)PO'@'N^=90B$*\FO%-O$L40S"
M%')>1,'2%WQK FMEC<:89)(8B^3][9/8TPBB-&BM(44JJ%( 54))W@^DZ6C'
MOY;IK"'U(QDQENEB<3$"/#&<;:M"P'J_U72-33 HW2C-P\QC$N[O]Z.W( \-
MR>FL_98HI9OSESJ-X?\ )W6)X:C*O4 I>U9;4KT().M:/8;/?8V1K_C+3[:>
MAH$,DM21/&I^1-)LW2/WH&#:M5NI1AZ3H.EB1FECQS4R+=RK$WY+;SSU C*H
MOR \K[F_8UW./%FR7QZRA\2Q!3];+IQN>15D>-,;TE:%(J/C!*XYU %)140=
M$$*'R]3-['\0Z2$_S!Q'6NUNS^XJ_I&</)6[\V%I:W>=MJ.Z&V45*9:2"7>=
MLKYL:VO/"=6C>*_VB";\L^1W'_CQ$^*+3%GO)TV:V:7REQRFZ2.R98O234?I
MH[L;/4QO$Q4JIC[,]JHKK**14"5+4-J4>#]7_#FAZ=*<OK2DG%1:JM,H'5F'
MYSE\&:OK<T/7=<VP8!OG&UE&.;7<L-.\7NJ[.>2*5[_.NJY>1YE'(I&9?B0(
M$@:1C@.H ;3AX,Q^!S"BG?[@Z@34.]_&WQ1U=R0/1?P;J]EH^DSTY324MG,=
M11-?N9;:-T3;NK&"DK@ZS=;MYRU)RGRR6VI6%T6R&@0CD=M @!UN>8>:?*Q1
MQ0@F&^$^#<AV^8[N21:2Y/S/E-E6J3):V%GD1?&A4@5(T$$R'0-.)IA\*06#
M2%J!!.3^']+3[?UG5U];4TS3S&$8&M-3Z.K#3G*5+&9!J<2,H[Y2J2!<9=KI
ML8QC&1(%E+<9L%-MH%K4G-)=9.IM/LJ#13KQ/FB]GO\ >I1AIJUL]O9,D\4/
MJ#K9!'8Z]#K?C _'NEVVIWD-CNLU!QJ!_=]HO*6V5R4'-5UH>A=NZ1-^8[7C
MF4]0O\RG!X;KD.J\/FR,,A8/,GYB49997+<XW>=9,]6@N]@_##X"_09Z[;V?
MAWW'O?\ M(/CJ/PD]IV_I^E+4G4I0)-1U6-L]=:3<.979A&C#C-_$7:RU'VC
M0N;*V_V-8N/B+X\70C=KWBSYL,AYU\&N?,B=,,4L5VO&GBK)R[/]I.J,B^*I
M*^8RRS[4LC,F-42QTZ*(0%=%55>J??B.CVA0 G@O5?1^VT?5=*<9SU=^K*1&
M1.HDX:<M1*G$(Q)2V\I$!96WL]AZKW/<=K-V1B1AE)0M=\B!*X-WM% C'F5"
M1ZK-^14P4I1YI7&"U73]O4;G'($E0HC?2MEQC/GQ"AU$#L5'U[$[.S]?0/Q9
MW?9ZOHL=*&H;XFKMQJ&7N-&<2V <QYMSC%UU@^GP[S4[V+(]N[37.EB,8R$K
MVKQPW;QYZL+?:H786O&KC&P:(#EG>2//Y@!@@KXG78E04/?1((W_ # WKCOP
M3/0[?7[CZCM!@QQ-S*/<LN-SS*)G^ ==#Z]!U=.%"M?;Q+2/D#S7/^P#O[-'
M-(GBGB+RQRA,KT-T=;,V1FSO+JRME7R@40Y"T*!3W)ZGI/HH#I'2?4#Q/\:3
MT=?7TOII*,C49KO (G9D<(+GF@^]^5Z#I_3@LJ''^^L910LX_P!?*D]G*#,*
M;S%$1:X16NKBYS IM%D?NQ;W+X87I:SHG:3LD[[Z!4 -+.^6[/3)3'!MN,:I
M"Q5:6FAP-U9PYTI+MP\AAC3BP,-(5C%6W8F/ WD+X<XM:K>X:[:0Y,F)3]YM
M4ZZG!T3W425)[1R+$! 0D?*@!25I4H%%VINUYR2_IDHD:H9)$5O"")Y*B%4J
MC%1*\FYSDYH*X:RBE*TVWT&K7F+G!NNK-\E$/9[F(N&PFV^'WUN))T-,SSU=
M-50U_P!8%'L5#\_&KW'I?9U4)I7+6HR48VW*06V^,7FN.J/JRS=.3'@*I!,F
M*X_7'/2\SA&XMEO'+?R&Q@2VR!C'W^0&T"4N*0E*$*2\CU]_156U@*ZU)*E
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MO_/?TKW_ '/]7_CU'Z9\?RC_ ,NN/PCL?];\B?I_G0O_ /+\QOPM_.3^>/\
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M7*^;?XQI^W)_-\]"ZWC60<WYKY6-;AG;*L)A>*)9!(%$6/&\@98W[ADKK@2
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MNT#=Q X%9BPAR1^+9]D^7S3$&)<7Q&%8]M':;U7%61\R7,<1$)IF)ZA!I*3
MV6+XS:(SCJ%1+XREU1%G=2.Z(2BK;FM1ZAZEHZD#9$@SJ3F<F.XTV418 RWV
M,MH4+RBFP[2)7FAH;JC M2+*_=7^0'4R6D ]D_\ R/Z?H/R^OU[^,3ZG(../
M/Q?PUS6/GJ_:'C^OZ/\ 7//7)!5WUV.OJ/I_=]1XC*&_/A/YF/DOC#C%\>7_
2 *_UZ]O%O2ZSPNEUGA=+K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
